Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 10/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.49 |
| ▸ | RELA | Q04206 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7238213 | 0.83 | RAB9A (0.97) | RAB9ASMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL18114078 | 0.79 | MAPT (0.65) | RAB9ASMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL5329732 | 0.77 | RAB9A (0.80) | RAB9ASMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL3136087 | 0.77 | RAB9A (0.62) | RAB9ASMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL12987199 | 0.76 | RAB9A (0.73) | RAB9ASMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL7230888 | 0.75 | RAB9A (1.00) | RAB9ASMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL17625953 | 0.73 | RAB9A (0.58) | RAB9ASMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL12987788 | 0.73 | RAB9A (0.57) | RAB9ASMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL19627009 | 0.72 | RAB9A (0.72) | RAB9ASMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL15801276 | 0.72 | PLA2G10 (0.64) | RAB9ASMN1; SMN2MAPTNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| US-20200071277-A1 | PHOTOREACTIVE LIGANDS AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2020-03-05 | — | — | US | disclosed |
| EP-2963036-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-9562044-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9562044-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2963036-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | Astellas Pharma Inc. (JP) | 2016-01-06 | — | — | EP | disclosed |
| CN-103342703-A | N-[4-(benzofuran-5-yl)thiazole-2-yl] amide as well as preparation method and application for same | UNIV HUNAN | 2013-10-09 | — | — | CN | disclosed |
| US-20020177594-A1 | Inhibitors of histone deacetylase | ABBOTT LABORATORIES | 2002-11-28 | — | — | US | disclosed |
| WO-2002046129-A2 | INHIBITORS OF HISTONE DEACETYLASE | ABBOTT LABORATORIES (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | CLTB, CRYAB, CRYAA | RAB9A 634/4885SMN1; SMN2 4860/4885MAPT 3004/4885 |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, CHRM5 | RAB9A 2669/4885SMN1; SMN2 1804/4885MAPT 700/4885 |
| US-20020177594-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC3 | RAB9A 2823/4885SMN1; SMN2 1367/4885MAPT 1179/4885 |
| US-20200071277-A1 | PHOTOREACTIVE LIGANDS AND USES THEREOF | CLTB, CRYAB, CRYAA | RAB9A 634/4885SMN1; SMN2 4860/4885MAPT 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.